ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

When Is a Doctor Too Old to Practice?

Simon M. Helfgott, MD  |  September 18, 2017

Steady hands, nerves of steel: The endoscopic transphenoidal hypophysectomy is a delicate neurosurgical procedure. Using a three-dimensional microscope and a powerful magnetic resonance imaging machine to guide them, the surgeon must meticulously dissect the throat tissues, navigate through the palate and the sinuses to reach the base of the skull where the pea-sized master gland,…

Filed under:OpinionRheuminationsSpeak Out RheumWorkforce Tagged with:agingCareerclinicianpatient carephysicianPractice Managementretirementrheumatologistrheumatologywork-life balance

Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  September 17, 2017

Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:apataceptApprovalsClinicaldrugFDAMedicationOrenciaoutcomepsoriatic arthritisRAResearchRheumatoid arthritisrheumatologySafetysirukumabstudyTreatmenttrial

Demand for Revision Total Knee Arthroplasty Is on the Rise

Karen Appold  |  September 15, 2017

In the next five to 10 years, the frequency of revision total knee arthroplasty is expected to grow 600%, due to the rise in obesity in the U.S. population and increase in primary knee replacement surgeries. Physicians can use different tools to help decrease the risk of premature implant failure and improve patient outcome…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Hospital for Special Surgerysurgerytotal knee arthroplastytotal knee replacement

Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2017

Citing safety concerns, the FDA Arthritis Advisory Committee voted against recommending approval of sirukumab for treating adults with RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Drug SafetyFDAFood and Drug AdministrationRheumatoid Arthritis (RA)sirukumab

What Do Diabetes, Islet Cells & Autoimmunity Have in Common?

Simon M. Helfgott, MD  |  August 15, 2017

“Man may be the captain of his fate, but he is also the victim of his blood sugar.” —Wilfrid Oakley, MB BChir, an early pioneer in diabetes care Perusing the list of the most notable medical achievements in the 20th century, a reader may conclude that the discovery of insulin should rank in a category…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:AutoimmuneCharles BestdiabetesdiscoveryDr. Frederick Bantingglucoseinsulinislet cellsPathogenesispatient careTreatment

TNF Stabilizes Inflammatory RNA in Synoviocytes

Lara C. Pullen, PhD  |  August 14, 2017

A recent study has helped researchers gain insight into the genome-wide regulation of mRNA stability in RA fibroblast-like synoviocytes (FLS). Chronic exposure of FLS to tumor necrosis factor appears to increase mRNA stability, enhancing the expression of inflammatory genes and the perpetuation of synovitis…

Filed under:ConditionsRheumatoid Arthritis Tagged with:fibroblast-like synoviocytesRheumatoid Arthritis (RA)RNAtumor necrosis factor inhibitor

What Rheumatologists Are Paid

Richard Quinn  |  July 28, 2017

A 2017 survey showed that rheumatologists’ pay has plateaued. And according to Anne Bass, MD, many cognitive fields, such as pediatrics and endocrinology, remain underpaid due to the current reimbursement structure…

Filed under:Professional Topics Tagged with:CompensationrheumatologistrheumatologysalariesSalary

Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA

Michele B. Kaufman, PharmD, BCGP  |  July 20, 2017

Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:amputationApprovalsbonecanagliflozindrugFDAFracturesGiant Cell ArteritisMedicationMyocardial infarctionNSAIDOsteoporosisrheumatologyriskromosozumabSafetytocilizumabTreatment

How to Document a Patient’s Medical History

From the College  |  July 13, 2017

The levels of service within an evaluation and management (E/M) visit are based on the documentation of key components, which include history, physical examination and medical decision making. The history component is comparable to telling a story and should include a beginning and some form of development to adequately describe the patient’s presenting problem. To…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCenters for Medicare & Medicaid Services (CMS)CodingDocumentationguidelineoffice visitpatient carephysicianpractice management. evaluationReimbursementrheumatologistrheumatology

Sanofi to Invest Further in Biologics

Matthias Blamont  |  June 14, 2017

PARIS (Reuters)—Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential. In contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsSanofi

  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 65
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences